CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+7.53%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$162M
(+18%)
Cap. Flow
+$137M
Cap. Flow
% of AUM
12.79%
Top 10 Holdings %
Top 10 Hldgs %
37.33%
Holding
532
New
105
Increased
323
Reduced
47
Closed
36
Top Buys
| 1 |
Apple
AAPL
|
$9.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$7.06M |
| 3 |
NVIDIA
NVDA
|
$6.46M |
| 4 |
Microsoft
MSFT
|
$6.23M |
| 5 |
ProShares Ultra Gold
UGL
|
$5.73M |
Top Sells
| 1 |
Alibaba
BABA
|
$5.72M |
| 2 |
GSK
GSK
|
$5.14M |
| 3 |
Pinduoduo
PDD
|
$3.46M |
| 4 |
Procter & Gamble
PG
|
$2.91M |
| 5 |
Synopsys
SNPS
|
$2.45M |
Sector Composition
| 1 | Technology | 38.06% |
| 2 | Healthcare | 25.43% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Communication Services | 10.24% |
| 5 | Financials | 3.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
426
Tango Therapeutics
TNGX
$772M
| $70.4K | 0.01% |
22,777
+2,170
| +11% | +$6.71K |
|
427
Precigen
PGEN
$1.3B
| $69.6K | 0.01% |
62,099
+6,762
| +12% | +$7.57K |
|
428
Aquestive Therapeutics
AQST
$656M
| $68.8K | 0.01% |
+19,333
| New | +$68.8K |
|
|
SLN
429
Silence Therapeutics
SLN
$269M
| $68.5K | 0.01% |
+9,963
| New | +$68.5K |
|
|
RVNC
430
DELISTED
Revance Therapeutics, Inc.
RVNC
| $67.6K | 0.01% |
22,243
+2,082
| +10% | +$6.33K |
|
431
Trevi Therapeutics
TRVI
$854M
| $67.1K | 0.01% |
+16,298
| New | +$67.1K |
|
|
SLRN
432
DELISTED
ACELYRIN
SLRN
| $66.8K | 0.01% |
21,273
+2,077
| +11% | +$6.52K |
|
433
Wolfspeed
WOLF
$196M
| $66.6K | 0.01% |
10,000
+5,000
| +100% | +$33.3K |
|
434
Voyager Therapeutics
VYGR
$235M
| $65.7K | 0.01% |
11,583
+1,094
| +10% | +$6.2K |
|
435
Absci
ABSI
$368M
| $63.8K | 0.01% |
+24,354
| New | +$63.8K |
|
436
Kanzhun
BZ
$11.1B
| $63.5K | 0.01% |
+4,600
| New | +$63.5K |
|
437
Rigel Pharmaceuticals
RIGL
$742M
| $62.8K | 0.01% |
+3,735
| New | +$62.8K |
|
438
Estee Lauder
EL
$32.1B
| $62.5K | 0.01% |
+833
| New | +$62.5K |
|
439
iShares US Technology ETF
IYW
$23.1B
| $60.6K | 0.01% |
380
+379
| +37,900% | +$60.5K |
|
440
Atea Pharmaceuticals
AVIR
$267M
| $60K | 0.01% |
17,909
+1,672
| +10% | +$5.6K |
|
|
ITOS
441
DELISTED
iTeos Therapeutics
ITOS
| $59.5K | 0.01% |
7,747
+723
| +10% | +$5.55K |
|
442
Vanda Pharmaceuticals
VNDA
$272M
| $59.2K | 0.01% |
12,363
+1,152
| +10% | +$5.52K |
|
443
AC Immune
ACIU
$229M
| $56.6K | 0.01% |
20,970
+1,949
| +10% | +$5.26K |
|
444
Lexicon Pharmaceuticals
LXRX
$396M
| $56.6K | 0.01% |
76,650
+7,123
| +10% | +$5.26K |
|
445
Foghorn Therapeutics
FHTX
$326M
| $55.6K | 0.01% |
+11,788
| New | +$55.6K |
|
446
Amylyx Pharmaceuticals
AMLX
$910M
| $54.9K | 0.01% |
14,535
+1,441
| +11% | +$5.45K |
|
447
4D Molecular Therapeutics
FDMT
$340M
| $54.6K | 0.01% |
9,802
-193
| -2% | -$1.08K |
|
448
C4 Therapeutics
CCCC
$194M
| $53.9K | 0.01% |
+14,967
| New | +$53.9K |
|
449
Larimar Therapeutics
LRMR
$337M
| $52.4K | ﹤0.01% |
+13,529
| New | +$52.4K |
|
|
ARTV
450
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$88.2M
| $51.9K | ﹤0.01% |
+5,150
| New | +$51.9K |
|